Secukinumab, a novel anti-IL-17A antibody, exhibits low immunogenicity in clinical trials and human in vitro assays. Issue 1 (October 2016) - Kolbinger, Frank; Blauvelt, Andrew; Armstrong, April; Fox, Todd; Huang, Jiaqing; Liang, Eric; Karle, Annette; Spindeldreher, Sebastian; Bruin, Gerard; Reich, Kristian